Biotech Values

[DewDiligence]

Re: Biosimilar drugs in the U.S.

>Are there going to be 20 different generic companies making generic Epogen? No. There will be two, or three, or four, and the prices will come down eventually between 50 and 80 percent.<

This prediction from the W.R. Hambrecht & Co. analyst is at odds with the report by the Citi analysts (#msg-13366231) that forecasts only 10-30% price discounts for generic biologics. I’m inclined to side with Citi on this one.